Diabetes Mellitus, Type I

Metabolic Diseases
1
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
1
Low Molecular Weight Sulfated DextranPhase 21 trial
Active Trials
NCT00790439WithdrawnEst. Oct 2009
Leadiant Biosciences
Leadiant BiosciencesMD - Rockville
1 program
CarnitineN/A1 trial
Active Trials
NCT00351234Completed200Est. Apr 2007
G
GentiBioMA - Cambridge
1 program
blood drawN/A1 trial
Active Trials
NCT06860516Recruiting50Est. Jun 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Allergy TherapeuticsLow Molecular Weight Sulfated Dextran
GentiBioblood draw
Leadiant BiosciencesCarnitine

Clinical Trials (3)

Total enrollment: 250 patients across 3 trials

NCT00790439Allergy TherapeuticsLow Molecular Weight Sulfated Dextran

Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney Transplant

Start: Jul 2008Est. completion: Oct 2009
Phase 2Withdrawn

HLA Demographics Study in Adults With Type 1 Diabetes

Start: Jun 2025Est. completion: Jun 202650 patients
N/ARecruiting

Carnitine Levels and Carnitine Supplementation in Type I Diabetes

Start: Oct 2004Est. completion: Apr 2007200 patients
N/ACompleted

Related Jobs in Metabolic Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 250 patients
3 companies competing in this space